Qhov txawv ntawm Retatrutide, Tirzepatide thiab Semaglutide yog dab tsi?

Qhov tseem ceeb ntawm qhov sib txawv ntawm peb peptides yog tus naj npawb ntawm cov tshuaj hormones metabolic uas lawv qhib, uas ncaj qha txiav txim siab lawv qhov hnyav tag nrho thiab kev ua haujlwm glycemic.

Qhov tseem ceeb tshaj qhov sib txawv ntawm peb lub molecules yog tus naj npawb thiab hom receptors lawv qhib, uas ncaj qha tsav kev ua tau zoo:

• Semaglutide: Ib leeg GLP-1 receptor agonist, feem ntau tsim ib lub hom phiaj metabolic peptide kho.
• Tirzepatide: Dual GIP / GLP-1 receptor agonist, thawj zaug pom zoo dual agonist chav kho mob.
• Retatrutide: Triple GIP/GLP-1/glucagon receptor agonist, thawj-hauv- cov neeg sib tw hauv chav kawm tam sim no nyob rau theem 3 kev txhim kho.

Retatrutideua tiav qhov hnyav dua qhov nruab nrab hnyav dua li tirzepatide thiab semaglutide hauv Phase 3 kev rog rog, tsis pom qhov hnyav poob toj siab txog 104 lub lis piam ntawm kev kho mob ntev.

Poob Qhov Ua Tau Zoo

Qhov kev sib piv no siv cov ntaub ntawv los ntawm txhua qhov tshuaj qhov tseem ceeb ntawm Phase 3 kev rog rog, ntawm qhov kev sim siab tshaj plaws / pom zoo koob tshuaj:

Thaum hloov kho rau lub sijhawm kho zoo sib xws, rettrutide tswj tau qhov hnyav dua li 25-30% piv rau tirzepatide, thiab ze li ob npaug ntawm cov nyhuv semaglutide. Tshwj xeeb tshaj yog, rettrutide kuj pom tias tsis muaj qhov hnyav hnyav txog li 104 lub lis piam ntawm kev txuas ntxiv ua raws- nce hauv siab -BMI pawg, qhov sib txawv tseem ceeb ntawm cov kev kho mob uas twb muaj lawm qhov kev poob qis feem ntau yog toj siab tom qab 60-72 lub lis piam.

Tag nrho peb cov peptides txo qis HbA1c qib tau zoo, tab sis rettrutide ua rau muaj kev poob qis dua nyob rau hauv cov neeg mob ntshav qab zib thaum sib piv tirzepatide cov piam thaj- txo qis zog.

Kev tswj glycemic hauv hom 2 mob ntshav qab zib

Tag nrho peb tus neeg sawv cev muab kev kho mob muaj txiaj ntsig zoo txhim kho glycemic. Retatrutide muab kev poob phaus ntau dua hauv cov neeg T2D ntau dua li cov neeg sib piv, nrog HbA1c txo qhov sib npaug nrog cov thawj coj ob leeg.

Retatrutide muaj ze li zoo tib yam kev mob plab hnyuv thiab kev kho mob tsis tu ncua raws li tirzepatide thiab semaglutide, txawm tias nws cov glucagon receptor ntxiv.

Safety Profile Sib piv

Thoob plaws tag nrho peb txoj kev kho mob, cov xwm txheej tsis zoo tshaj plaws yog kab mob plab hauv qhov xwm txheej, ua raws li GLP-1 chav kawm tshuaj:

Cov kev phiv tshwm sim: xeev siab, raws plab, cem quav, ntuav - feem ntau me me mus rau nruab nrab, thiab muaj ntau nyob rau hauv koob tshuaj - theem titration.

Kev kho mob tsis tu ncua vim muaj cov xwm txheej tsis zoo:

• Semaglutide 2.4mg: ~ 10%
• Tirzepatide 15 mg: ~ 10-12%
• Retatrutide 12 mg: 11.3%

Txawm hais tias ntxiv lub hom phiaj thib peb receptor, rettrutide tsis qhia cov khoom siv ntau dua ntawm cov xwm txheej tsis zoo piv rau kev pom zoo dual thiab ib leeg agonists, raws li cov ntaub ntawv muaj nyob rau theem 3. Lub sijhawm ntev -cov ntaub ntawv kev nyab xeeb ntawm lub plawv rau retatrutide tseem nyob hauv ntau qhov txuas ntxiv -center follow-up.

Semaglutide thiab tirzepatide tau txais kev pom zoo thoob ntiaj teb cov tshuaj lag luam, thaum rettrutide tseem yog qhov kev tshawb nrhiav Phase 3 tsuas yog muaj rau cov kws kho mob R & D API khoom thaum nruab nrab xyoo 2026.

Cov xwm txheej patent yog qhov tseem ceeb rau kev txhim kho generic thiab biosimilar. Semaglutide muaj pes tsawg leeg patents tab tom pib tas rau hauv cov cheeb tsam xaiv, thaum tirzepatide thiab rettrutide tseem nyob hauv kev tiv thaiv patent rau yav tom ntej.

Rau cov kev txhim kho generic/biosimilar: Ua ntej semaglutide lossis tirzepatide, uas tau tsim kev lag luam, kev tswj xyuas meej meej, thiab cov patent tas sij hawm nyob rau hauv ntau lub cheeb tsam.

Rau yav tom ntej - tiam tshiab tsim kev tsim kho: Ua ntej rettrutide, raws li nws triple -agonist mechanism muab kev ua tau zoo tshaj plaws thiab sawv cev rau cov nthwv dej tom ntej ntawm kev kho mob metabolic.

Rau thaum ntxov- kev tshawb fawb theem pib nrog kev siv nyiaj tsawg: Semaglutide API yog qhov dav tshaj plaws thiab tus nqi - kev xaiv zoo rau cov pov thawj- ntawm - cov tswv yim kev tshawb fawb.

Rau MASH/NAFLD tsom rau kev tshawb fawb: Retatrutide's glucagon-kev kho mob siab oxidation muab nws qhov tshwj xeeb kho kom zoo dua ib leeg thiab dual agonists.

Retatrutide sawv cev rau qhov ua tau zoo tshaj plaws metabolic peptide nyob rau hauv lig - theem kev loj hlob, xa cov ntaub ntawv zoo tshaj qhov kev poob phaus piv rau ob qho tib si semaglutide thiab tirzepatide thaum tuav qhov sib piv me ntsis kev nyab xeeb profile hla Phase 3 cov ntaub ntawv soj ntsuam kuaj.

• Retatrutide muab cov txiaj ntsig zoo tshaj qhov poob phaus piv rau ob qho tib si tirzepatide thiab semaglutide, nrog rau kev sib piv kev nyab xeeb hauv Phase 3 kev sim.
• Tirzepatide thiab semaglutide tseem yog tus qauv ntawm kev saib xyuas rau kev pom zoo siv kho mob, nrog tsim cov saw hlau thiab cov txheej txheem kev pom zoo thoob ntiaj teb.
• Rau yav tom ntej - saib ntev - lub sij hawm R & D pipelines tsom rau kev kho mob metabolic, rettrutide yog qhov zoo tshaj plaws tom ntej - tiam peptide neeg sib tw muaj rau kev tshawb fawb API.

Tsis lees paub: Kab lus no yog rau cov ntaub ntawv xov xwm nkaus xwb thiab tsis yog cov lus qhia kho mob. Tag nrho cov ntaub ntawv kho mob tau muab los ntawm cov txiaj ntsig tau tshaj tawm rau pej xeem thaum nruab nrab -2026. Tag nrho cov khoom siv yog siv rau kev siv tshuaj R & D thiab kev tsim khoom nkaus xwb, tsis yog rau kev siv tus kheej lossis kev tswj tus kheej.